Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Primary Prevention Cohort: Apixaban	57,560
Overall Study	STARTED	Primary Prevention Cohort: Warfarin	90,636
Overall Study	STARTED	Secondary Prevention Cohort: Apixaban	18,216
Overall Study	STARTED	Secondary Prevention Cohort: Warfarin	27,153
Overall Study	COMPLETED	Primary Prevention Cohort: Apixaban	57,560
Overall Study	COMPLETED	Primary Prevention Cohort: Warfarin	90,636
Overall Study	COMPLETED	Secondary Prevention Cohort: Apixaban	18,216
Overall Study	COMPLETED	Secondary Prevention Cohort: Warfarin	27,153
Overall Study	NOT COMPLETED	Primary Prevention Cohort: Apixaban	0
Overall Study	NOT COMPLETED	Primary Prevention Cohort: Warfarin	0
Overall Study	NOT COMPLETED	Secondary Prevention Cohort: Apixaban	0
Overall Study	NOT COMPLETED	Secondary Prevention Cohort: Warfarin	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05321810/flow